Solanezumab: too late in mild Alzheimer's disease?

被引：43
|
作者：
不详
机构：
来源：
LANCET NEUROLOGY | 2017年 / 16卷 / 02期
关键词：
D O I：
10.1016/S1474-4422(16)30395-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [1] "BREAKTHROUGH" DRUG IN ALZHEIMER'S DISEASE Need for a trial of solanezumab in mild Alzheimer's disease
    Torgerson, David
    BMJ-BRITISH MEDICAL JOURNAL, 2015, 351
  • [2] Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
    Honig, Lawrence S.
    Vellas, Bruno
    Woodward, Michael
    Boada, Merce
    Bullock, Roger
    Borrie, Michael
    Hager, Klaus
    Andreasen, Niels
    Scarpini, Elio
    Liu-Seifert, Hong
    Case, Michael
    Dean, Robert A.
    Hake, Ann
    Sundell, Karen
    Hoffmann, Vicki Poole
    Carlson, Christopher
    Khanna, Rashna
    Mintun, Mark
    DeMattos, Ronald
    Selzler, Katherine J.
    Siemers, Eric
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04): : 321 - 330
  • [3] Trial of solanezumab for mild dementia due to Alzheimer's disease
    Pickrell, William O.
    Robertson, Neil P.
    JOURNAL OF NEUROLOGY, 2018, 265 (09) : 2162 - 2162
  • [4] Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
    Imbimbo, Bruno P.
    Ottonello, Simone
    Frisardi, Vincenza
    Solfrizzi, Vincenzo
    Greco, Antonio
    Seripa, Davide
    Pilotto, Alberto
    Panza, Francesco
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (02) : 135 - 149
  • [5] Solanezumab for Alzheimer's disease
    Samadi, Hossein
    Sultzer, David
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (06) : 787 - 798
  • [6] Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease
    Doggrell, Sheila A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (12) : 1189 - 1192
  • [7] Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
    Doody, Rachelle S.
    Thomas, Ronald G.
    Farlow, Martin
    Iwatsubo, Takeshi
    Vellas, Bruno
    Joffe, Steven
    Kieburtz, Karl
    Raman, Rema
    Sun, Xiaoying
    Aisen, Paul S.
    Siemers, Eric
    Liu-Seifert, Hong
    Mohs, Richard
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (04): : 311 - 321
  • [8] Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
    Siemers, Eric R.
    Sundell, Karen L.
    Carlson, Christopher
    Case, Michael
    Sethuraman, Gopalan
    Liu-Seifert, Hong
    Dowsett, Sherie A.
    Pontecorvo, Michael J.
    Dean, Robert A.
    Demattos, Ronald
    ALZHEIMERS & DEMENTIA, 2016, 12 (02) : 110 - 120
  • [9] Trial of Solanezumab in Preclinical Alzheimer's Disease
    Sperling, Reisa A.
    Donohue, Michael C.
    Raman, Rema
    Rafii, Michael S.
    Johnson, Keith
    Masters, Colin L.
    van Dyck, Christopher H.
    Iwatsubo, Takeshi
    Marshall, Gad A.
    Yaari, Roy
    Mancini, Michele
    Holdridge, Karen C.
    Case, Michael
    Sims, John R.
    Aisen, Paul S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (12): : 1096 - 1107
  • [10] Solanezumab and the amyloid hypothesis for Alzheimer's disease
    Le, David G.
    Hunter, Sally
    Brayne, Carol
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 355
12345